Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Aug 06, 2024
Episode
232
Soundcloud
Share
In this special episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu moderate a discussion on the seminal PROFILE-1001 trial that brought us the versatile tyrosine kinase inhibitor crizotinib. Crizotinib was the first approved ALK inhibitor and the first approved ROS1 inhibitor, and it played a huge role in the emergence of the targeted therapy paradigm.
Guest
Stephen Liu
MD
Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Ignatius Ou
MD
Professor of Medicine and Hamoui Salous Endowed Chair in Thoracic Oncology Research
The University of California, Irvine
Alice Shaw
MD
Chief of Strategic Partnerships
Dana Farber Cancer Institute
Board Member of the American Association of Cancer Research
Benjamin Solomon
PhD, MBBS, FRACP
Professor and Consultant Medical Oncologist
Peter MacCallum Cancer Center
IASLC Board of Directors
